Agenda – Medical Affairs & Communications Launch Readiness Summit

  • DAY ONE
  • Day Two

DAY ONE

 MONDAY, DECEMBER 2, 2019

9:00AM – 9:45AM

DEFINE INDUSTRY BEST PRACTICES FOR NEW PRODUCTS PRE-COMMERCIALIZATION
Daniel Snyder, Senior Director Medical Affairs, REVANCE THERAPEUTICS

9:45AM – 10:30AM

EXECUTE TIMELINE PLANS EARLY AND OFTEN FOR PRE-LAUNCH PRODUCTS
Barry Lubarsky, Senior Medical Director, Medical Affairs, ALKERMES

10:30AM – 11:00AM

COFFEE AND NETWORKING BREAK

11:00AM – 12:00PM

PANEL: EFFECTIVE COLLABORATION WITH TEAMS: KEY FACTORS FOR A SUCCESSFUL LAUNCH
Daniel Jones, Medical Director and U.S. Lead — M.S. Franchise, Interferons, Opicinumab, EMD SERONO
Tyson Tu, Director and Head, Medical Communications, ALKERMES

12:00PM – 1:00PM

NETWORKING LUNCH

1:00PM – 1:45PM

OPERATE MODELS TO ENSURE FIELD TEAMS RECEIVE TRAINING ON PRE-LAUNCH ACTIVITIES
Howard Berkowitz, Respiratory and Immunology Medical Science Liaison — U.S. Field-Based Medical Affairs NJ/NYC Region, SANOFI

1:45PM – 2:30PM

CASE STUDY: OVERSEE EXECUTION OF GLOBAL MEDICAL AFFAIRS STRATEGY FOR A LAUNCH PRODUCT AND FIELD
Steven Zhang, Vice President, Medical Affairs, KALA PHARMACEUTICALS

3:00PM – 3:45PM

DETERMINE SUCCESS OF STRATEGIC PROCESS AND LAUNCH KPIS
Alison Martens, Sr. Medical Science Liaison, LA JOLLA PHARMACEUTICALS

3:45PM – 4:15PM

LEVERAGE ROLES AND MANAGEMENT OF CROSS-FUNCTION INTERACTIONS
Scott McConnell, Scientific Affairs Consultant, KALEIDO BIOSCIENCES


Day Two

 TUESDAY, DECEMBER 3, 2019

9:00AM – 9:45AM

UNDERSTAND BEST PRACTICES FOR PROJECT DEVELOPMENT WITH COMMUNICATION TEAMS FROM PRE- TO POST-LAUNCH
Kanchan Relwani, Vice President, Head of Medical Affairs, ALKERMES

9:45AM – 10:30AM

EDUCATE THE IMPORTANCE OF MEDICAL AFFAIRS TO THIRD PARTY PARENT COMPANIES
Courtney Zeni, Associate Medical Director, Product Development, NOVEN PHARMACEUTICALS

10:30AM – 11:00AM

COFFEE AND NETWORKING BREAK

11:00AM – 11:45AM

EXPLORE AND UNDERSTAND THE IMPORTANCE OF EXTERNAL STAKEHOLDER MANAGEMENT
Irene von Hennigs, Pharm.D., Executive Director and TA Medical Lead Complement, Hematology and Nephrology, ALEXION PHARMACEUTICALS
Ray Pourfarzib, Ph.D., Executive Director and TA Medical Lead Metabolics, ALEXION PHARMACEUTICALS

11:45AM – 12:30PM

COMPLIANTLY WORK WITH COMMERCIAL AND REGULATORY TEAMS IN SMALL PHARMA ORGANIZATIONS
Kavita Aggarwal, Vice President, Medical Affairs , DOVA PHARMACEUTICALS

12:30PM – 1:30PM

LUNCHEON

1:30PM – 2:15PM

EXPLORE PARTNERSHIPS WITH COMMERCIAL TEAMS FOR BENEFICIAL CONTENT MANAGEMENT
Jenny Zhang, Associate Director, Portfolio and Strategy Launch Lead, Global Medical Affairs — Oncology, EMD SERONO

2:15PM – 2:45PM

REGULATORY AND COMPLIANCE RISKS DURING THE PRE-APPROVAL PERIOD: HOW TO DEVELOP AN EFFECTIVE AND COMPLIANT ROLE FOR MEDICAL AND COMMUNICATIONS DURING PRE- AND POST-LAUNCH
Howard L. Dorfman, Adjunct Professo, SETON HALL UNIVERSITY SCHOOL OF LAW; and Founder, H.L. DORFMAN PHARMACEUTICAL CONSULTING, LLC

3:15PM – 3:30PM

UNDERSTAND THE KEY ROLE OF PUBLICATION STRATEGIES FROM A GLOBAL AND REGIONAL LEVEL
Richa Attre, Associate Director, Publications Management, Medical Affairs, REGENERON PHARMACEUTICALS

3:30PM – 4:15PM

ENSURE SALES READINESS AND ENABLE LOCAL SALES TEAMS THROUGH TRAINING AND FIELD COMMUNICATIONS
Lubna Jamal, Real-World Evidence Consultant , PROGENICS PHARMACEUTICALS

4:15PM – 4:15PM

CONFERENCE CONCLUDES